Myriad Genetics, Inc. (MYGN)'s HRD Score Detects Loss of DNA Repair Function in Ovarian Cancer
10/11/2012 9:38:46 AM
SALT LAKE CITY, Oct. 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the British Journal of Cancer demonstrated the ability of the Company's Homologous Recombination Deficiency (HRD) Assay to detect loss of DNA repair in ovarian tumors. The study, entitled, "Patterns of Genomic Loss of Heterozygosity Predict Homologous Recombination Repair Defects in Epithelial Ovarian Cancer," confirmed, with highly statistically significant results, the relationship between Myriad's HRD score and tumors deficient in DNA repair.
comments powered by